Evidence map›Paper›PMID 36331681›Full record

Trial reportJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2023

Impact of first-line cryoablation for atrial fibrillation on healthcare utilization, arrhythmia disease burden and efficacy outcomes: real-world evidence from the Cryo Global Registry.

Giulio Zucchelli, K R Julian Chun, Surinder Kaur Khelae, Csaba Földesi, Fred J Kueffer, Kelly A van Bragt, Fernando Scazzuso, Young-Keun On, Fawzia Al-Kandari, Ken Okumura and 1 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02752737 (Cryo Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02752737 completednot on this map

Cryo Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform

Typeobservational_patient_registrySponsorMedtronic Cardiac Ablation SolutionsRan2016 to 2024Enrolled5,385ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Contemporary Trends in Pulsed Field Ablation for Cardiac Arrhythmias.Journal of cardiovascular development and disease · 2024
    Review
  4. Review
  5. Regional variations in patient selection and procedural characteristics for cryoballoon ablation of atrial fibrillation in the cryo global registry.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024
    Article
  6. Review
  7. Selected Advances in the Anti-arrhythmic Management of Atrial Fibrillation: 2023.The Journal of innovations in cardiac rhythm management · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 9 countries.

Giulio ZucchelliSecond Division of Cardiology, Azienda Ospedaliero Universitaria Pisana, Via Roma, 67, 56126, Pisa, Italy. g.zucchelli@ao-pisa.toscana.it.ORCID http://orcid.org/0000-0001-7274-4541
K R Julian ChunCardioangiologisches Centrum Bethanien, Frankfurt, Germany.ORCID http://orcid.org/0000-0002-2355-6015
Surinder Kaur KhelaeInstitut Jantung Negara, National Heart Institute, Kuala Lumpur, Malaysia.
Csaba FöldesiGottsegen György Országos Kardiovaszkuláris Intézet, Budapest, Hungary.ORCID http://orcid.org/0000-0002-5033-117X
Fred J KuefferMedtronic, Inc, Minneapolis, MN, USA.
Kelly A van BragtMedtronic, Inc, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-4118-4291
Fernando ScazzusoInstituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-1623-0535
Young-Keun OnSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-1025-7283
Fawzia Al-KandariChest Disease Hospital, Kuwait City, Kuwait.
Ken OkumuraSaiseikai Kumamoto Hospital, Kumamoto, Japan.ORCID http://orcid.org/0000-0002-3202-7203
Cryo Global Registry Investigators
Medtronic (United States) · USAzienda Ospedaliera Universitaria Pisana · ITCardiovascular Center Bethanien · DEChest Diseases Hospital · KWGottsegen National Cardiovascular Center · HUInstituto Cardiovascular de Buenos Aires · ARNational Heart Institute · MYSaiseikai Kumamoto Hospital · JPSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCryoballoon ablation (CBA) is an effective first-line treatment for symptomatic atrial fibrillation (AF), as recently demonstrated by three randomized trials. This sub-analysis of the Cryo Global Registry aims to examine current clinical practices of first-line CBA.

methodsAF patients treated with first-line CBA were compared to CBA in antiarrhythmic drug (AAD)-refractory patients at 12 months. Efficacy was examined using time-to-first atrial arrhythmia recurrence following a 90-day blanking period. Healthcare utilization was evaluated by repeat ablations and hospitalizations. Disease burden was examined by assessing quality of life (QOL) and patients' reporting of symptoms.

resultsOf 1394 patients, 433 (31.1%) were treated with first-line CBA, which was more frequent in high-volume centers. Serious procedure-related adverse event rates were similar. Efficacy at 12 months was higher in the first-line group (87.8 vs. 81.6%, HR

conclusionsIn this global real-world experience, first-line CBA in patients with symptomatic AF is effective, with a larger symptom reduction compared with CBA after AAD failure and without a difference in healthcare utilization at mid-term follow-up. CLINICAL

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT02752737.

Indexed as

Atrial FibrillationCatheter AblationCryosurgeryAnti-Arrhythmia AgentsCost of IllnessHumansPatient Acceptance of Health CareQuality of LifeRecurrenceTreatment OutcomeAnti-Arrhythmia AgentsAtrial fibrillationCatheter ablationCryoballoonFirst-line ablationRegistry

Identifiers

PMID36331681
OpenAlexW4308185904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.